Multiple myeloma (MM), characterised by the clonal expansion of plasma cells within the bone marrow, is the second most common haematological malignancy. MM murine models have shown that hypoxia is a specific feature of MM with a significant increased hypoxia marker hypoxia-inducible factor-1 (HIF-1) *α* in the bone morrow of MM tumour-bearing mice ([@bib6]). *HIF1-α* was reported to be expressed in 95.4% of CD138-purified myeloma cell samples from 329 previously untreated myeloma patients ([@bib5]). Myeloma cells of patients with t(4;14) translocations showed a significantly higher HIF-1*α* expression, whereas a significant downregulation of *HIF-1α* expression was described in hyperdiploid patients ([@bib5]). Two independent studies ([@bib3]; [@bib10]) also confirmed the expression of HIF in bone marrow biopsy specimens from MM patients. HIF-1*α* is overexpressed in MM cells growing within the bone marrow hypoxic environment. Recent studies have explored the effects of HIF-1*α* inhibition in MM. Using *HIF-1α* shRNA, [@bib15] reported a limited impact on MM cell proliferation and survival *in vitro*. However, a significant inhibition of MM-induced angiogenesis and bone lesions was reported *in vivo* ([@bib15]). Treatment of MM cells with a small antisense oligonucleotide against *HIF-1α* (EZN-2968) was shown to induce cell cycle arrest and a metabolic shift with a significant increased of ATP production by oxidative phosphorylation ([@bib2]).

HIF-1 is a heterodimeric transcription factor constituted of O~2~-regulated HIF-1*α* and constitutively expressed HIF-1*β* subunits. In hypoxic conditions, HIF-1*α* is translocated into nucleus, heterodimerises with HIF-1*β* and binds to hypoxia response element DNA sequence. Then, p300/CBP co-activators are recruited to initiate the transcription of a diverse group of genes involved in hypoxia response ([@bib14]).

According to these data, disrupting the complex formed by HIF-1*α* and p300 appeared to be a promising approach to target HIF ([@bib3]; [@bib15]; [@bib13]).

Chetomin, a metabolite complex, produced by several fungi of the genus *Chaetomium*, disrupts the ability of tumours to adapt to hypoxia by blocking the HIF pathway ([@bib9]). Chetomin targets p300, a transcriptional co-activator, by disrupting the structure of its CH1 domain. By this way, chetomin makes impossible the interaction between p300 and HIF-1*α*, which results, in a mitigation of hypoxia-inducible transcription ([@bib9]; [@bib13]). The aim of this study was to investigate the interest of chetomin as a strategy for MM treatment.

Materials and methods
=====================

Human myeloma cell lines (HMCL, *n*=10) XG-1, XG-2, XG-6, XG-7, XG-11, XG-13, XG-19, RPMI8226, LP1 and SKMM2 were obtained as previously described ([@bib11]) or purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig, Germany) and American Type Culture Collection (Rockville, MD, USA). Microarray data are deposited in the ArrayExpress public database (accession numbers E-TABM-937 and E-TABM-1088). Human myeloma cell lines were cultured with graded chetomin (Sigma, St Louis, MO, USA) concentrations. Human myeloma cell lines\' cell growth was quantified with a Cell Titer Glo Luminescent Assay (Promega, Madison, WI, USA) and the 50% inhibitory concentration (IC50) was determined using GraphPad Prism software (<http://www.graphpad.com/scientific-software/prism/>).

Gene expression profiling (GEP) of MM cells (MMCs) were obtained from two independent large patients\' cohorts: the Heidelberg--Montpellier (HM, *N*=206) cohort (ArrayExpress public database under accession number E-MTAB-362) ([@bib4]; [@bib12]) and the publicly available cohort from University of Arkansas for Medical Sciences (UAMS, Little Rock, AR, USA, cohort treated with total therapy 2, *N*=345) (GEO, <http://www.ncbi.nlm.nih.gov/geo/>, accession number GSE2658). Patients presenting with previously untreated MM (*N*=206) at the university hospitals of Heidelberg and Montpellier have been included in the study approved by the ethics committee of Montpellier (DC-2008-417) and Heidelberg after written informed consent in accordance with the Declaration of Helsinki. Clinical parameters and treatment regimens of the MM patients included in the HM cohort were previously described ([@bib12]).

Bone marrow of patients presenting with previously untreated MM (*N*=6) at the university hospital of Montpellier was obtained after patients\' written informed consent in accordance with the Declaration of Helsinki and agreement of the Montpellier University Hospital Centre for Biological Resources (DC-2008-417). Primary myeloma cells of patients were cultured with or without graded concentrations of chetomin and MMC cytotoxicity evaluated using anti-CD138-phycoerythrin monoclonal antibody (Immunotech, Marseille, France) as described ([@bib12]).

Results
=======

A combined high *HIF-1α* and *EP300* expression, defined using maxstat R package ([@bib8]), in MMCs could predict for shorter overall survival (OS) in two independent cohorts of patients (*P*=0.007 in the HM cohort *N*=206 and *P*=0.0001 in the UAMS-TT2 cohort *N*=345) ([Figure 1](#fig1){ref-type="fig"}). Low-risk patients accounted for 85.4% with a not reached median OS and high-risk patients for 14.6% with a median OS of 54.9 months in the HM cohort ([Figure 1](#fig1){ref-type="fig"}). In the UAMS TT2 cohort, a significant better survival in *EP300*^low^/*HIF-1α*^low^ group (median OS not reached) compared with *EP300*^high^/*HIF-1α*^high^ group (median OS of 56 months; *P*=0.0001) was also found ([Figure 1](#fig1){ref-type="fig"}). Patients with *EP300*^high^/*HIF-1α*^high^ expression have also a median event-free survival significantly decreased compared with those of the *EP300*^low^/*HIF-1α*^low^ group (*P*=0.004 in the HM cohort and *P*=0.0003 in the UAMS TT2 cohort).

Gene set enrichment analysis was performed to compare gene expression profiles of patients myeloma cells with *EP300*^high^/*HIF-1α*^high^ and *EP300*^low^/*HIF-1α*^low^ expression. Genes overexpressed in MM molecular subgroups CD2 and LB (low bone disease) were significantly enriched in *EP300*^low^/*HIF-1α*^low^ group ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"} and [Supplementary Tables S1 and S2](#sup1){ref-type="supplementary-material"}). Patients of the *EP300*^high^/*HIF-1α*^high^ group were characterised by a significant enrichment of genes related to embryonic stem cells, DNMT1 targets and proliferation ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"} and [Supplementary Tables S3--S5](#sup1){ref-type="supplementary-material"}). According to these data, we investigated the correlation between *HIF-1**α**/EP300* expression and MM plasma cell labelling index or GEP-based growth proliferation index (GPI) ([@bib4]). No significant correlation between HIF-1*α*/EP300 expression and myeloma cell proliferation or GPI was identified ([Supplementary Figures S2A and B](#sup1){ref-type="supplementary-material"}).

The effect of chetomin was investigated in 10 different HMCL representative of the patients\' molecular heterogeneity ([@bib11]). Chetomin induced a dose-dependent inhibition of cell growth in all investigated HMCL, independently of the their molecular heterogeneity ([@bib11]) with a median IC50 of 4.1 n[M]{.smallcaps} (range: 2.29--6.89 n[M]{.smallcaps}) ([Figure 2A](#fig2){ref-type="fig"}). Chetomin treatment induced a significant downregulation of HIF-1*α* target gene expression ([@bib15]) including *VEGF, IL-8* and *CLL3* proangiogenic genes ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}).

We investigated the effects of chetomin on primary MM cells of patients (*n*=6, [Supplementary Table S6](#sup1){ref-type="supplementary-material"}) co-cultured with their bone marrow microenvironment ([@bib12]). After 4 days of treatment, cells were enumerated and the fraction of viable myeloma cells (CD138^+^), non-myeloma cells (CD138^−^) and haematopoietic progenitors (CD34^+^) were determined by flow cytometry ([@bib12]). Chetomin induced a dose-dependent toxicity on myeloma cells of patients, with a median IC50 of 1.56 n[M]{.smallcaps} without affecting the survival of bone marrow normal cells or CD34+ haematopoietic stem cells ([Figure 2B](#fig2){ref-type="fig"}). Interestingly, *EP300*^high^/*HIF-1α*^high^ myeloma cells of patient 2 were the most sensitive to low-dose chetomin treatment ([Supplementary Table S6](#sup1){ref-type="supplementary-material"} and [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}).

It was previously demonstrated that HIF-1*α* suppression enhanced the anti-myeloma activity of melphalan and lenalidomide treatment ([@bib7]; [@bib15]). Low concentration of chetomin (2 n[M]{.smallcaps}) significantly enhanced the anti-myeloma activity of lenalidomide and melphalan ([Supplementary Figures S4A and B](#sup1){ref-type="supplementary-material"}).

Discussion
==========

According to our data, targeting HIF-1*α*/p300 interaction appears to be a potent strategy to target hypoxia pathway in MM. Studies have demonstrated a positive regulation of HIF1-*α* by MM growth factors including IL6 and IGF-1 ([@bib2]), a correlation between HIF1-*α* expression and MYC deregulation ([@bib17]) and a role of HIF1-*α* in MM angiogenesis through stimulation of VEGF ([@bib1]; [@bib3]). Interestingly, chetomin treatment induced a significant anti-myelomatous activity without toxicity on bone marrow normal cells and haematopoietic progenitors ([Figure 2B](#fig2){ref-type="fig"}).

High *HIF-1α* and *EP300* expression are associated with a poor prognostic value in MM ([Figure 1](#fig1){ref-type="fig"}). The prognostic value of *EP300*^high^/*HIF-1α*^high^ expression was compared with usual prognostic factors---ISS, t(4;14), del17p, or published GEP-based risk scores including UAMS-HRS, IFM score, GPI and RS score. Using univariate Cox analysis on HM cohort, all these factors had prognostic value ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}). When these parameters were compared two by two, *EP300*^high^/*HIF-1α*^high^ expression tested with *β*2m, del17p, GPI, HRS, IFM and ISS remained significant ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}). When tested together, only RS, *β*2m and t(4;14) kept prognostic value ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}). *EP300*^high^/*HIF-1α*^high^ MM patients are characterised by a significant enrichment of genes related to proliferation, stemness and DNMT1 targets. We previously reported genes signatures shared by MM cells and normal stem cells linked with a prognostic value and that might be important in malignant stem cell biology ([@bib8]). Furthermore, HIF-1*α* represents an interesting target to eradicate cancer stem cells in haematological malignancies including lymphoma and acute myeloid leukemia ([@bib16]). Chetomin could be useful to target MM patients with a high myeloma-stem cell score and aggressive disease ([@bib8]). Furthermore, chetomin enhances the toxicity of lenalidomide and melphalan on MM cells as previously reported with HIF-1-*α* depletion ([@bib7]; [@bib15]).

Altogether, these data suggest that chetomin or HIF-1-*α*/p300 inhibitors may be of clinical value in MM and especially for patients characterised by a high *EP300* and *HIF-1α* expression.
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![**High *HIF1-α* and *EP300* expression in MMCs could predict for shorter overall and event-free survival (EFS) in two independent cohorts of patients.** (**A**) Patients of the HM cohort (*n*=206) were ranked according to increasing *EP300* and *HIF-1α* expression and a maximum difference in OS was obtained using the Maxstat R function. High EP300 and HIF-1*α* expression is also associated with a shorter EFS in the HM cohort (*n*=206). (**B**) High *EP300* and *HIF1α* expression is associated with a poor prognosis (OS and EFS) in an independent cohort of 345 patients (LR-TT2 cohort).](bjc201620f1){#fig1}

![**Chetomin, induces a dose-dependent inhibition of cell growth in HMCL and has toxic effects on primary myeloma cells.** (**A**) HMCL were cultured for 4 days in 96-well flat-bottom microtitre plates in RPMI 1640 medium, 10% fetal calf serum, 2 ng ml^−1^ interleukin six culture medium (control), and graded concentrations of chetomin. At day 4 of culture, the viability was assessed by CellTiter-Glo Luminescent Cell Viability Assay. The IC50 (concentration responsible for 50% of the maximal inhibitory effect), was determined using GraphPad PRISM software. Data are mean values±s.d. of five experiments determined on sextuplet culture wells. (**B**) Mononuclear cells from six patients with MM were cultured for 4 days in the presence of IL-6 (1 ng ml^−1^) with or without graded concentrations of chetomin. At day 4 of culture, the viability and total cell count were assessed and the percentage of (i) CD138^+^ viable plasma cells, (ii) CD34^+^ haematopoietic stem cells and (iii) non-myeloma cells was determined by flow cytometry. Results are median values from six patients.](bjc201620f2){#fig2}
